[1] |
ZHANG Chi, CHEN Jiahui, LIN Jinyi, WANG Yan, ZHANG Sijia, ZHU Wei, CHENG Leilei.
Validation of a scale for evaluating the cardiovascular risk after breast cancer therapy: the clinical scale for breast cancer treatment related cardiovascular toxicity
[J]. China Oncology, 2022, 32(1): 54-60.
|
[2] |
JIN Yizi, LIN Mingxi, ZHANG Jian.
Targeting DNA damage response deficiency in the treatment of breast cancer
[J]. China Oncology, 2022, 32(1): 61-67.
|
[3] |
Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition) .
Expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition)
[J]. China Oncology, 2022, 32(1): 80-89.
|
[4] |
ZHANG Xiaoyan , LI Qingxiang , LIU Yong , LI Hang , QIU Lijuan , FENG Xinran , TAN Liming .
A study on the correlation between HMGB1 and clinical characteristics and immune function in patients with breast cancer
[J]. China Oncology, 2021, 31(9): 783-788.
|
[5] |
CAO Ailing, CAO Zhe, ZHOU Jian.
Effects of docetaxel combined with thymosin α1 on number of Treg in immune microenvironment of rats with breast cancer and its mechanism
[J]. China Oncology, 2021, 31(9): 799-806.
|
[6] |
YAO Jia , LI Guanqiao , YANG Shiping , SU Huiluan .
Effect of hsa-miR-98-5p/DKK3 signal axis on biological behavior of breast cancer cells
[J]. China Oncology, 2021, 31(9): 807-816.
|
[7] |
CONG Binbin, WANG Yongsheng.
Treatment landscape and challenges of managing the hormone receptor-positive early breast cancer
[J]. China Oncology, 2021, 31(8): 689-696.
|
[8] |
YANG Shipeng , LIU Ying , WANG Xinyue , YANG Yang , QUAN Jishu , LIN Zhenhua .
Clinical significance of PKLR overexpression in the pancreatic cancer
[J]. China Oncology, 2021, 31(8): 704-713.
|
[9] |
ZHU Yihui, LI Ting, HU Xichun.
Clinical research progress and prospect of trastuzumab deruxtecan
[J]. China Oncology, 2021, 31(8): 754-761.
|
[10] |
DING Gaofeng, GUO Leiming, LU Yufei.
The relationship between expressions of HER2 and BRCA1 and radiotherapy sensitivity in breast cancer patients
[J]. China Oncology, 2021, 31(7): 589-595.
|
[11] |
XIE Jinfang , CAO Chunyu , REN Xue , TIAN Jiajun , LÜ Yafeng , HUANG Xiaofei .
Effects of sulforaphane on epithelial-mesenchymal transition, proliferation and migration of mouse breast cancer 4T1 cells
[J]. China Oncology, 2021, 31(7): 605-615.
|
[12] |
CAO Dalong, ZHU Wenkai, SHI Guohai, ZHANG Hailiang, WANG Ziliang, YE Dingwei.
The influence of PRUNE2 gene point mutation on proliferation, apoptosis, invasion and migration of prostate cancer DU145 cells
[J]. China Oncology, 2021, 31(6): 441-446.
|
[13] |
ZHU Junjun, GE Naijian, YANG Yefa.
Current status and prospects of migration of radioactive 125 I seed implanted in malignant tumor
[J]. China Oncology, 2021, 31(4): 257-262.
|
[14] |
QIAO Tingting , GE Shujing , LUO Yuan , LU Chengrong , DUAN Lianning .
Mechanism of inhibition of epithelial-to-mesenchymal transition by phosphorylated H2AX in lung cancer cells
[J]. China Oncology, 2021, 31(4): 277-284.
|
[15] |
ZENG Feng , LI Dan , SHAO Xinxin , ZHANG Nengying , CHEN Xinghan , CHENG Xiaoming .
Prognostic nomogram for elderly breast cancer patients with 1-2 positive nodes who underwent mastectomy and different axillary surgeries: a SEER-based study
[J]. China Oncology, 2021, 31(4): 323-329.
|